Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study

ABSTRACT:

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC12297733 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature